protect
blood
suppli
emerg
pathogen
role
pathogen
inactiv
although
risk
infect
blood
transfus
rel
low
breakthrough
infect
still
occur
transfusionrel
fatal
caus
infect
continu
report
blood
test
mani
potenti
danger
pathogen
current
paradigm
increas
safeti
blood
suppli
develop
implement
laboratori
screen
method
restrict
donor
criteria
consid
larg
number
known
pathogen
fact
pathogen
continu
emerg
clear
util
new
test
donor
restrict
continu
challeng
consid
cost
develop
implement
new
screen
assay
loss
potenti
donor
risk
test
error
despit
improv
safeti
blood
compon
test
remain
reactiv
approach
blood
safeti
contamin
organ
must
identifi
sensit
test
develop
contrast
pathogen
inactiv
proactiv
strategi
design
inactiv
pathogen
enter
blood
suppli
almost
pathogen
inactiv
technolog
target
nucleic
acid
allow
inactiv
varieti
nucleic
acidcontain
pathogen
within
plasma
platelet
red
blood
cell
thu
provid
potenti
reduc
transfusiontransmit
diseas
howev
widespread
use
pathogen
inactiv
technolog
realiz
proven
safe
efficaci
costprohibit
elsevi
inc
right
reserv
develop
increasingli
sensit
laboratori
screen
method
restrict
donor
criteria
greatli
decreas
risk
transmiss
mani
pathogen
blood
transfus
howev
transfus
still
riskfre
transfusionrel
fatal
infect
continu
report
blood
current
test
mani
potenti
danger
known
pathogen
addit
emerg
new
agent
west
nile
viru
wnv
demonstr
potenti
threat
blood
suppli
continu
emerg
worldwid
test
donor
deferr
method
current
use
screen
blood
suppli
may
offer
complet
protect
emerg
infecti
agent
strategi
develop
donor
screen
test
method
pathogen
emerg
success
reduc
risk
transfus
transmiss
mani
virus
includ
human
immunodefici
viru
hiv
hepat
c
viru
hcv
hepat
b
viru
hbv
fig
howev
intervent
substanti
delay
implement
blood
bank
system
alreadi
heavili
burden
multipl
test
step
stringent
donor
screen
fig
unit
state
blood
test
antibodi
human
tlymphotroph
viru
htlv
iii
hbv
hcv
treponema
pallidum
spirochet
caus
syphili
test
also
perform
presenc
hepat
b
surfac
antigen
hbsag
hcv
wnv
nucleic
acid
implement
investig
new
drug
applic
process
furthermor
like
nucleic
acid
test
nat
hbv
hepat
viru
parvoviru
nucleic
acid
ad
requir
next
sever
year
moreov
american
associ
blood
bank
aabb
recent
issu
requir
accredit
mandat
test
platelet
compon
bacteri
contamin
although
clear
continu
need
develop
new
technolog
protect
safeti
blood
suppli
also
clear
ad
new
test
andor
donor
restrict
known
emerg
pathogen
feasibl
pathogen
inactiv
may
promis
altern
expand
test
donor
deferr
technolog
introduct
must
proven
safe
efficaci
costprohibit
pathogen
inactiv
proactiv
technolog
chemic
compound
ad
blood
result
multipl
log
reduct
infect
viabil
varieti
pathogen
includ
virus
bacteria
protozoa
sever
pathogen
inactiv
agent
includ
amotosalen
inactin
methylen
blue
mb
solvent
deterg
current
clinic
develop
clinic
use
pathogen
inactiv
technolog
offer
potenti
improv
safeti
blood
suppli
pathogen
even
current
unknown
technolog
specif
individu
pathogen
review
focu
emerg
viral
bacteri
parasit
pathogen
threaten
blood
suppli
current
avail
detect
method
dilemma
balanc
need
reduc
risk
transfusiontransmit
infect
econom
feasibl
requir
addit
test
role
pathogen
inactiv
improv
safeti
blood
suppli
also
explor
emerg
pathogen
new
reemerg
migrat
drugresist
infecti
agent
whose
incid
infect
either
increas
within
past
decad
threaten
increas
near
futur
categori
includ
complet
new
agent
well
agent
evolv
part
caus
widespread
environment
degrad
global
warm
region
warfar
popul
displac
econom
induc
migrat
blood
donor
rural
urban
area
less
develop
countri
ongo
loss
polit
basic
health
infrastructur
around
world
factor
contribut
emerg
new
pathogen
includ
chang
human
demograph
evolv
effect
new
technolog
industri
econom
ic
develop
land
use
intern
travel
commerc
microbi
adapt
chang
tabl
chang
technolog
industri
practic
contribut
emerg
pathogen
resist
treatment
exampl
overprescript
antibiot
widespread
use
livestock
soap
household
cleaner
contribut
resist
mani
strain
bacteria
human
demograph
econom
develop
land
use
intern
travel
commerc
breakdown
public
health
measur
result
increas
spread
vector
mosquito
tick
carri
pathogen
well
spread
pathogen
humantohuman
contact
addit
pathogen
problemat
one
countri
becom
problemat
brought
anoth
countri
pathogen
adapt
chang
make
test
less
effici
genet
chang
often
relat
antivir
antibiot
vaccin
passiv
immunotherapi
put
pressur
pathogen
escap
mutat
number
factor
affect
pattern
pathogen
emerg
complex
imposs
predict
next
emerg
pathogen
epidem
exampl
lack
predict
recent
worldwid
sever
acut
respiratori
syndrom
sar
epidem
agent
least
arbovirus
includ
flavivirus
wnv
close
rel
wnv
st
loui
enceph
viru
western
equin
enceph
viru
eastern
equin
enceph
viru
potenti
becom
threat
blood
suppli
optim
condit
present
infect
arbovirus
often
asymptomat
result
enceph
case
death
enceph
sever
sequela
neurolog
complic
arbovirus
pose
particular
threat
blood
suppli
arboviru
infect
asymptomat
asymptomat
infect
donor
result
transmiss
recipi
viremia
preced
clinic
diseas
antibodi
product
infecti
donor
could
donat
without
detect
wnv
epidem
unit
state
demonstr
arboviru
infect
could
emerg
time
pose
signific
threat
blood
transfus
safeti
wnv
epidem
establish
unit
state
appear
origin
egyptian
strain
viru
larg
increas
report
number
human
wnv
infect
north
america
compar
previou
year
case
report
unit
state
case
canada
year
recogn
wnv
could
transmit
blood
transfus
twentythre
confirm
case
transfusiontransmit
wnv
report
transmit
via
red
blood
cell
rbc
platelet
plasma
novemb
blood
bank
industri
met
address
problem
transfusiontransmit
wnv
juli
routin
nat
implement
investig
new
drug
applic
process
four
relat
distinct
flavivirus
distant
rel
wnv
caus
diseas
known
dengu
fever
dengu
hemorrhag
fever
flavivirus
anoth
exampl
arbovirus
threaten
safeti
blood
suppli
dengu
reach
epidem
proport
asia
south
america
intern
travel
dengu
potenti
becom
epidem
unit
state
two
case
transfus
transmiss
dengu
rbc
report
hong
kong
hepat
virus
exampl
emerg
viral
pathogen
virus
caus
liver
diseas
result
cirrhosi
liver
hepatocellular
carcinoma
sever
type
hepat
virus
e
identifi
hepat
b
c
readili
transmit
blood
transfus
hepat
e
rare
transmit
transfus
although
sever
hepat
virus
identifi
still
modest
proport
hepat
attribut
known
virus
hepat
g
viru
tt
viru
ttv
candid
nona
e
hepat
extens
studi
fail
demonstr
agent
caus
posttransfus
hepat
diseas
sen
virus
variant
ttv
may
caus
posttransfus
hepat
sen
virus
shown
preval
donor
pool
clear
correl
virus
hepat
shown
transmiss
viral
hepat
particularli
hbv
hcv
blood
donor
recipi
transfus
blood
compon
plasma
deriv
well
document
transfus
transmiss
hbv
hcv
dramat
reduc
test
highlight
residu
risk
transfusiontransmit
hepat
possibl
emerg
undiscov
hepat
virus
human
parvoviru
nonenvelop
singlestrand
dna
viru
transmit
blood
infect
gener
thought
benign
peopl
immunocompet
caus
erythema
infectiosum
arthralgia
aplast
crisi
patient
rbc
defect
chronic
anemia
immunocompromis
patient
fetal
hydrop
transfus
transmiss
report
primarili
recipi
plasma
deriv
recipi
clot
factor
concentr
manufactur
larg
plasma
pool
rare
incid
transmiss
via
blood
compon
also
report
anoth
exampl
previous
complet
unknown
viru
recent
emerg
threat
coronaviru
caus
sar
viru
transmit
anim
human
be
region
china
spread
global
intern
travel
case
sar
report
estim
death
attribut
sar
sever
acut
respiratori
syndrom
outbreak
report
primarili
hong
kong
special
administr
region
peopl
republ
china
taiwan
singapor
canada
vietnam
unit
state
smaller
outbreak
report
sever
countri
includ
australia
franc
germani
philippin
thailand
evid
transfusiontransmit
sar
infect
viru
present
blood
affect
individu
could
allow
transmiss
via
transfus
blood
compon
avian
influenza
anoth
emerg
pathogen
recent
receiv
consider
media
attent
avian
influenza
contagi
diseas
caus
virus
normal
infect
bird
less
commonli
pig
cross
speci
barrier
infect
human
be
caus
sever
diseas
high
mortal
sinc
middecemb
grow
number
asian
countri
report
outbreak
avian
influenza
chicken
duck
highli
pathogen
strain
known
identifi
caus
outbreak
outbreak
report
vietnam
thailand
yet
known
avian
influenza
transmiss
transfus
detect
serolog
test
viral
antigen
antibodi
standard
detect
infecti
diseas
agent
blood
suppli
sinc
identif
hbsag
today
blood
routin
screen
antibodi
htlviiii
hbv
hcv
presenc
hbsag
countri
hiv
antigen
although
serolog
test
effect
result
decreas
risk
hiv
hepat
b
c
transfusiontransmit
infect
presenc
bwindow
period
q
period
infect
appear
detect
antigen
host
antibodi
necessit
develop
nat
nucleic
acid
test
hiv
hcv
decreas
risk
transfus
transmit
infect
agent
donat
hiv
donat
hcv
fig
although
risk
transfus
transmiss
hiv
hcv
hbv
greatli
reduc
serolog
test
nat
breakthrough
infect
still
occur
one
case
breakthrough
transmiss
hiv
report
singapor
case
american
red
cross
one
case
transfus
transmiss
hcv
report
breakthrough
case
may
caus
viremia
nat
sensit
cutoff
logist
cost
reason
nat
current
perform
minipool
plasma
donat
dilut
donor
plasma
pool
decreas
sensit
test
howev
singledonor
test
costeffect
nucleic
acid
test
reduc
window
period
virus
elimin
pressur
singleunit
nat
mani
feel
singleunit
nat
feasibl
unless
autom
avail
multipl
pathogen
detect
singl
nat
unit
state
routin
nat
investig
new
drug
donor
deferr
use
prevent
transfus
transmiss
wnv
longterm
benefit
measur
reduc
transfus
transmiss
wnv
unknown
time
estim
although
nat
perform
potenti
infecti
donor
miss
low
viral
load
window
phase
mp
busch
person
commun
hemagglutin
assay
avail
detect
parvoviru
blood
compon
polymeras
chain
reaction
pcr
assay
develop
use
clinic
studi
detect
viru
plasma
blood
routin
screen
viru
current
test
detect
dengu
known
arbovirus
blood
suppli
similarli
test
avail
detect
hepat
g
ttv
sen
virus
avian
influenza
viru
test
avail
sar
coronaviru
donor
deferr
question
implement
unit
state
although
test
donor
deferr
strategi
effect
greatli
reduc
risk
transfus
transmiss
virus
hiv
hcv
hbv
clear
method
elimin
risk
costor
laboreffect
develop
implement
serolog
test
nat
everi
known
emerg
pathogen
increas
donor
deferr
needlessli
deplet
blood
donor
pool
furthermor
method
reactiv
implement
pathogen
identifi
transfus
transmiss
report
develop
countri
transfusiontransmit
bacteri
contamin
platelet
common
microbiolog
caus
fatal
relat
transfus
transfusiontransmit
bacteri
infect
occur
rbc
well
platelet
occur
commonli
platelet
platelet
must
store
room
temperatur
maintain
viabil
function
combin
biolog
composit
platelet
media
creat
ideal
growth
environ
bacteria
risk
infect
hiv
hbv
hcv
per
unit
platelet
transfus
dramat
decreas
contrast
risk
transfusionassoci
bacteremia
chang
period
fig
risk
infect
bacteri
contamin
exce
viral
agent
base
unit
state
european
studi
overal
risk
contamin
similar
rbc
platelet
refriger
storag
bacteria
prolifer
rbc
preval
bacteri
contamin
platelet
approxim
u
wherea
highest
report
risk
yersinia
contamin
rbc
lead
symptom
approxim
per
countri
incid
sever
septic
episod
lead
signific
recipi
morbid
mortal
caus
transfus
contamin
blood
product
clearli
establish
may
high
u
apheresi
platelet
higher
pool
platelet
u
rbc
transfus
agent
organ
caus
bacteri
contamin
blood
compon
includ
skin
flora
common
enter
flora
environment
flora
contamin
may
occur
asymptomat
donor
bacteremia
rare
collect
faulti
collect
pack
leaki
seal
damag
tube
micropunctur
predomin
organ
isol
contamin
platelet
unit
skin
commens
coagulaseneg
staphylococci
identifi
speci
includ
streptococci
staphylococcu
epidermidi
bacillu
cereu
staphylococcu
aureu
pseudomona
fluorescen
pseudomona
aeruginosa
klebsiella
pneumonia
serratia
marcescen
serratia
liquefacien
anaerob
bacteria
includ
clostridium
perfringen
propionibacterium
acn
also
isol
howev
signific
anaerob
infect
context
platelet
transfus
known
red
blood
cell
associ
sepsi
usual
contamin
enterobacteriacea
grow
refriger
temperatur
yersinia
enterocolitica
liquefacien
speci
bacteria
commonli
detect
rbc
gramposit
gramneg
organ
shown
caus
transfusionassoci
sepsi
data
report
system
unit
state
bacon
unit
kingdom
shot
franc
suggest
case
transfusionrel
sepsi
caus
gramposit
organ
howev
fatal
caus
transfusionrel
sepsi
caus
gramneg
organ
bacterium
anaplasma
phagocytophilum
agent
human
granulocyt
ehrlichiosi
emerg
threat
blood
suppli
anaplasma
phagocytophilum
found
primarili
unit
state
europ
transmit
primarili
ixod
tick
seropreval
studi
connecticut
demonstr
seropreval
rate
approxim
donor
test
detect
problem
bacteri
contamin
blood
product
particularli
platelet
store
room
temperatur
recent
address
aabb
aabb
mandat
march
blood
bank
transfus
servic
method
limit
detect
bacteri
contamin
platelet
compon
howev
method
endors
aabb
avail
strategi
reduc
platelet
transfusionassoci
sepsi
includ
better
skin
prepar
use
singledonor
apheresi
platelet
divers
first
ml
collect
blood
pretransfus
bacteri
detect
pathogen
inactiv
improv
skin
disinfect
blood
donor
help
reduc
contamin
somewhat
isopropyl
alcohol
iodin
tinctur
found
effect
disinfect
chlorhexidin
glucon
disinfect
choic
allerg
iodin
use
singledonor
apheresi
platelet
versu
pool
donor
platelet
shown
one
studi
reduc
septic
platelet
transfus
reaction
transfus
transfus
increas
use
singledonor
platelet
year
decreas
like
fact
donor
one
chanc
donor
asymptomat
bacteremia
needl
stick
per
draw
unit
platelet
therefor
less
chanc
contamin
skin
divers
also
shown
result
reduc
bacteri
contamin
blood
product
howev
mostli
gramposit
organ
reduc
divers
usual
gramneg
organ
caus
fatal
bacteri
detect
wide
use
method
minim
risk
transfusiontransmit
sepsi
howev
method
high
level
sensit
factor
affect
sensit
efficaci
bacteri
detect
method
includ
bacteri
growth
kinet
size
initi
inoculum
sampl
time
platelet
prepar
sampl
volum
assay
sensit
time
posit
primari
difficulti
stem
fact
initi
inoculum
bacteria
often
extrem
low
colonyform
unit
per
millilit
detect
method
may
requir
hour
bacteria
grow
small
sampl
use
detect
bacteria
present
amount
time
requir
bacteria
grow
detect
level
vari
depend
growth
kinet
bacterium
mani
method
bacteri
detect
avail
howev
appar
length
list
mani
method
sensit
fig
cultur
appear
effect
sensit
approxim
colonyform
unit
per
millilit
univers
bacteri
detect
complic
amplif
enzym
deriv
bacteria
nucleic
acid
bcontaminationq
fact
common
find
small
amount
bacteri
nucleic
acid
healthi
donor
blood
although
cultur
sensit
method
drawback
system
bacteri
contamin
might
detect
transfus
taken
place
initi
inoculum
low
organ
slow
grower
may
take
day
cultur
posit
bacteri
detect
role
reduc
risk
transfusionassoci
sepsi
howev
even
method
effect
risk
reduc
hypothes
pathogen
inactiv
method
abl
reduc
risk
bacteri
contamin
minuscul
level
howev
date
method
shown
reduc
organ
exampl
organ
capabl
form
spore
may
elud
pathogen
reduct
techniqu
agent
parasit
agent
thought
constitut
greatest
threat
blood
suppli
protozoan
trypanosoma
cruzi
plasmodium
spp
babesia
spp
trypanosoma
cruzi
etiolog
agent
chaga
diseas
small
protozoan
parasit
primarili
found
latin
america
agent
repres
emerg
infect
unit
state
canada
infect
immigr
effect
treatment
unavail
infect
cruzi
clinic
manifest
includ
potenti
fatal
cardiac
gastrointestin
diseas
sign
symptom
usual
develop
sever
year
decad
infect
incid
cruzi
increas
unit
state
canada
last
year
emigr
infect
often
asymptomat
peopl
cruziendem
countri
last
year
case
transfusiontransmit
cruzi
report
unit
state
case
canada
case
transmiss
occur
case
via
platelet
other
compon
could
identifi
patient
receiv
multipl
blood
compon
donor
could
identifi
studi
demonstr
increas
number
seropreval
donor
chaga
diseas
difficult
recogn
report
incid
thought
underestim
multiyear
epidemiolog
studi
cruzi
lo
angel
blood
donor
demonstr
seropreval
rate
highrisk
popul
compris
peopl
born
spent
signific
amount
time
cruziendem
countri
increas
significantli
estim
us
blood
donor
posit
cruzi
antibodi
studi
suggest
blood
donor
antibodi
cruzi
evid
activ
parasitemia
peripher
blood
plasmodium
etiolog
agent
human
malaria
four
speci
plasmodium
plasmodium
falciparum
plasmodium
vivax
plasmodium
malaria
plasmodium
oval
known
caus
human
malaria
malaria
mosquitoborn
intracellular
parasit
rbc
liver
cell
caus
flulik
symptom
period
episod
fever
chill
relat
massiv
hemolysi
infect
erythrocyt
endem
area
malaria
main
indic
transfus
signific
caus
morbid
young
children
human
malaria
found
primarili
tropic
subtrop
region
howev
approxim
case
transfusionacquir
malaria
report
unit
state
annual
transfus
transmiss
primarili
via
rbc
platelet
also
implic
probabl
presenc
rbc
platelet
concentr
immigr
infect
individu
spread
parasit
bitten
local
mosquito
phenomenon
call
bairport
malaria
q
infect
mosquito
ride
airplan
caus
infect
near
airport
contribut
emerg
plasmodium
threat
blood
suppli
babesia
microti
one
agent
caus
zoonot
babesiosisa
mild
selflimit
diseas
caus
flulik
symptom
number
new
diverg
strain
babesia
includ
name
state
found
recent
identifi
babesia
intracellular
pathogen
rbc
transmit
deer
tick
human
babesiosi
report
primarili
north
america
europ
case
also
occur
latin
america
africa
southeast
asia
infect
treat
common
antibiot
howev
fatal
elderli
immunocompromis
asplen
individu
case
transfusiontransmit
b
microti
report
sinc
case
report
unit
state
case
also
report
japan
canada
pack
rbc
frequent
implic
case
also
report
frozen
deglycerol
rbc
platelet
base
estim
seropreval
rate
suggest
transfus
transmiss
underestim
recent
studi
seropreval
connecticut
highli
endem
area
lyme
diseas
carri
tick
carri
babesia
show
past
year
approxim
donor
screen
per
year
seroposit
babesia
although
number
vari
year
year
seroposit
individu
found
posit
pcr
test
threat
parasit
pose
blood
safeti
known
year
larg
ignor
agent
becom
increasingli
problemat
clear
step
must
taken
reduc
risk
transfus
transmiss
detect
trypanosoma
cruzi
blood
donor
usual
detect
serolog
test
latin
american
countri
blood
donat
screen
cruzi
antibodi
use
serolog
test
immunofluoresc
assay
hemagglutin
enzym
immunoassay
blood
unit
state
canada
screen
parasit
licens
screen
assay
unavail
septemb
meet
us
food
drug
administr
blood
product
advisori
committe
food
drug
administr
issu
request
manufactur
develop
submit
approv
antibodi
screen
test
cruzi
nucleic
acid
test
cruzi
costeffect
area
highli
endem
travel
histori
gener
effect
prevent
transmiss
malaria
howev
question
often
misinterpret
blood
donor
addit
travel
histori
needlessli
defer
thousand
blood
donor
unlik
infect
malaria
case
never
return
activ
donor
deferr
case
transfus
transmiss
malaria
come
donor
infect
plasmodium
home
countri
travel
mani
donor
exclud
unnecessarili
countri
serolog
nat
test
malaria
may
use
increas
number
potenti
blood
donor
diagnost
gold
standard
detect
babesia
immunofluoresc
assay
howev
licens
blood
screen
would
ineffici
test
larg
number
sampl
specif
sensit
enzym
immunoassay
b
microti
report
identif
secret
antigen
b
microti
could
lead
develop
test
detect
parasit
antigen
serum
sensit
pcr
assay
develop
varieti
babesia
dna
suggest
nat
may
use
detect
earli
acut
windowperiod
infect
variant
creutzfeldtjakob
diseas
vcjd
novel
human
prion
diseas
caus
infect
agent
bovin
spongiform
encephalopathi
bovin
spongiform
encephalopathi
contain
nucleic
acid
transmiss
caus
convers
normal
prion
protein
abnorm
hsheet
amyloid
structur
recent
report
suggest
risk
transmiss
vcjd
blood
transfus
also
increas
concern
chronic
wast
diseas
deer
elkassoci
prion
may
enter
blood
suppli
although
result
extens
reduct
risk
donor
select
test
elimin
pathogen
transfus
transmiss
continu
discoveri
pathogen
addit
new
test
becom
difficult
pathogen
inactiv
altern
develop
individu
test
donor
criteria
address
pathogen
individu
proactiv
effect
way
protect
blood
suppli
known
emerg
pathogen
goal
pathogen
inactiv
increas
safeti
blood
suppli
target
pathogen
without
compromis
therapeut
efficaci
blood
product
caus
advers
effect
recipi
two
method
inactiv
pathogen
prepar
fresh
frozen
plasma
ffp
method
prepar
platelet
concentr
introduc
clinic
practic
unit
state
europ
other
phase
clinic
develop
tabl
amotosalen
amotosalen
hydrochlorid
intercal
nucleic
acid
base
upon
activ
uva
light
form
coval
addit
monoadduct
diadduct
pyrimidin
base
dna
rna
adduct
form
interstrand
intrastrand
crosslink
within
genet
materi
block
replic
transcript
machineri
caus
cell
death
photochem
treatment
apheresi
pool
buffi
coat
platelet
amotosalen
plu
uva
light
shown
inactiv
broad
rang
virus
bacteria
protozoa
use
pathogen
inactiv
rbc
howev
light
absorb
hemoglobin
viscos
pack
rbc
preclin
data
treatment
platelet
shown
result
high
level
log
reduct
envelop
singlestrand
doublestrand
rna
dna
virus
provir
cellfre
cellassoci
singlestrand
rna
viru
duck
hbv
dhbv
model
hbv
singleand
doublestrand
dna
viru
human
hbv
strain
bovin
viral
diarrhea
viru
bvdv
model
hcv
singlestrand
rna
viru
human
hcv
hutchinson
strain
cytomegaloviru
cmv
doublestrand
dna
viru
tabl
preclin
studi
also
show
gramposit
gramneg
bacteria
platelet
sensit
inactiv
tabl
one
preclin
studi
also
demonstr
protozoan
cruzi
inactiv
platelet
plasma
greater
reduct
platelet
concentr
greater
reduct
plasma
comprehens
pharmaceuticalgrad
preclin
safeti
program
fail
find
specif
target
organ
toxic
reproduct
toxic
carcinogen
associ
amotosalen
preclin
studi
also
demonstr
treat
plasma
platelet
accept
function
characterist
clinic
data
clinic
studi
demonstr
amotosalen
nontox
treat
plasma
platelet
accept
function
characterist
two
random
control
phase
clinic
studi
eurosprit
sprint
trial
demonstr
photochem
treat
pct
buffi
coat
apheresi
collect
amicu
separ
platelet
therapeut
efficaci
compar
untreat
platelet
thrombocytopen
patient
primarili
patient
hematolog
malign
despit
hemostat
efficaci
patient
pct
group
lower
platelet
count
increment
shorter
transfus
interv
requir
platelet
transfus
refer
group
howev
subsequ
analysi
suggest
outcom
least
part
caus
inconsist
dose
transfus
patient
pct
group
receiv
significantli
high
proport
platelet
dose
pct
refer
patient
support
compar
note
apheresi
platelet
inocul
high
level
viru
treat
lmoll
amotosalen
jcm
uva
light
infect
virus
measur
use
establish
biolog
assay
preliminari
result
compound
belong
class
compound
call
frangibl
anchorlink
effector
frale
develop
inactiv
pathogen
rbc
frale
compound
contain
nucleic
acidtarget
intercal
group
effector
group
coval
addit
nucleic
acid
central
frangibl
bond
facilit
compound
degrad
frangibl
anchorlink
effector
activ
ph
shift
ad
pack
red
cell
suspend
residu
plasma
red
cell
addit
solut
neutral
ph
clinic
trial
result
healthi
volunt
patient
demonstr
transfus
rbc
well
toler
show
compar
recoveri
surviv
control
rbc
although
appar
clinic
consequ
observ
phase
clinic
trial
compound
halt
septemb
studi
patient
develop
antibodi
rbc
treat
inactin
pathogen
inactiv
technolog
develop
use
rbc
lowmolecularweight
compound
chemic
relat
binari
ethyleneimin
highli
select
nucleic
acid
coval
bind
nucleic
acid
result
inhibit
nucleic
acid
replic
translat
pathogen
genom
preclin
data
preclin
studi
demonstr
inactin
inactiv
broad
rang
virus
bacteria
well
mycoplasma
rbc
sever
studi
variou
virus
includ
envelop
nonenvelop
cellassoci
virus
found
sensit
inactin
treatment
tabl
preclin
studi
also
demonstr
inactiv
bacteria
inactin
treatment
rbc
spike
enterocolitica
p
fluorescen
pseudomona
putida
inactin
result
inhibit
bacteri
growth
rbc
unit
throughout
week
storag
inactin
also
inactiv
mycoplasma
whole
blood
rbc
reproduct
toxicolog
studi
rat
rabbit
also
demonstr
inactin
associ
reproduct
toxic
clinic
data
result
phase
clinic
studi
rbc
treat
inactin
demonstr
inactinetr
rbc
obtain
healthi
individu
store
day
met
vivo
criteria
requir
therapeut
use
unit
recent
report
phase
studi
inactin
halt
data
safeti
monitor
committe
concern
antibodi
respons
inactin
antibodi
respons
appear
associ
clinic
consequ
methylen
blue
mb
phenothiazin
dye
use
europ
inactiv
pathogen
ffp
sever
year
virucid
properti
phenothiazin
dye
recogn
sinc
earli
methylen
blue
ineffect
intracellular
virus
suggest
factor
viii
fibrinogen
sensit
mb
sever
studi
report
virucid
activ
anoth
phenothiazin
dye
dimethylmethylen
blue
dmmb
rbc
dimethylmethylen
blue
photoact
phenothiazin
dye
greater
affin
nucleic
acid
mb
dimethylmethylen
blue
plu
visibl
light
shown
inactiv
rna
dna
model
virus
includ
vesicular
stomat
viru
dhbv
leukocyt
natur
occur
vitamin
b
riboflavin
also
develop
nucleic
acidbind
agent
use
pathogen
inactiv
irradi
uva
visibl
light
intercal
riboflavin
molecul
form
crosslink
dna
rna
result
inactiv
nucleic
acidcontain
pathogen
riboflavinbas
pathogen
inactiv
system
plasma
platelet
rbc
current
develop
preclin
studi
demonstr
reduct
infect
sever
virus
includ
bvdv
pseudorabi
viru
well
bacteria
blood
product
data
indic
riboflavin
system
success
reduc
number
select
pathogen
platelet
concentr
despit
fact
signific
differ
exist
treat
control
vitro
variabl
specul
clinic
effect
product
significantli
differ
base
comparison
histor
data
product
routin
clinic
use
today
solventdeterg
sd
process
develop
use
ffp
clinic
practic
north
america
europ
process
shown
inactiv
sever
envelop
virus
ineffect
nonenvelop
virus
furthermor
sdffp
reduc
level
antithrombot
protein
antiplasmin
antitrypsin
may
respons
occurr
unexpect
venou
thrombot
event
largevolum
exposur
concern
commerci
factor
sdffp
longer
use
unit
state
howev
still
use
europ
countri
current
pathogen
inactiv
method
review
common
addit
compound
blood
compon
compound
target
genom
nucleic
acid
form
stabl
bond
nucleic
acid
thu
prevent
replic
one
method
sd
process
ffp
target
membran
disrupt
laboratori
studi
shown
method
effect
inactiv
broad
rang
virus
bacteria
protozoa
nucleat
cell
although
effect
vari
among
approach
exampl
sd
effect
nonenvelop
virus
mb
effect
inactiv
nucleat
cell
correspondingli
cellassoci
viru
although
pathogen
inactiv
consid
import
develop
blood
safeti
potenti
shift
current
paradigm
test
limit
need
consid
nucleic
acid
target
pathogen
inactiv
method
impact
risk
prion
caus
vcjd
possibl
chronic
wast
diseas
risk
need
continu
manag
donor
deferr
remov
contamin
agent
potenti
test
strategi
certain
nonenvelop
virus
tight
capsid
appear
rel
resist
inactiv
make
even
challeng
exampl
parvoviru
exist
donor
blood
titer
high
genom
equival
per
millilit
geqml
window
period
conserv
approach
would
retain
sensit
current
test
assur
level
viremia
well
document
pathogen
inactiv
effect
threshold
new
test
may
requir
even
set
univers
pathogen
inactiv
safeguard
variou
hightit
pathogen
could
potenti
bbreak
throughq
pathogen
inactiv
howev
note
high
viral
titer
report
express
geq
measur
quantit
pcr
small
fragment
base
viral
genom
contrast
viral
bacteri
protozoan
inactiv
experi
perform
use
infect
assay
detect
presenc
intact
viral
genom
requir
replic
diseas
transmiss
whether
geq
correspond
infecti
unit
viru
unequivoc
demonstr
publish
ratio
geq
infect
rang
parvoviru
assay
develop
base
inhibit
nucleic
acid
amplif
may
abl
extend
dynam
rang
pathogen
inactiv
studi
although
assay
answer
question
whether
geq
equal
infecti
virion
abl
extend
dynam
rang
pathogen
inactiv
experi
beyond
dynam
rang
infect
assay
also
note
pathogen
inactiv
compound
use
concentr
excess
amount
requir
inactiv
highest
report
geq
viral
titer
pathogen
inactiv
system
inactiv
bacteria
spore
exampl
b
cereu
repres
problem
resist
inactiv
howev
blood
compon
nutrientrich
media
spore
enter
veget
phase
contrast
spore
veget
form
b
cereu
highli
sensit
treatment
context
blood
compon
data
need
gener
show
whether
condit
exist
bacteria
would
form
spore
may
also
done
parasit
particularli
plasmodia
present
human
host
variou
form
may
vari
degre
access
pathogen
inactiv
compound
parasit
obtain
cultur
inactiv
experiment
pathogen
inactiv
method
review
involv
addit
compound
blood
compon
activ
either
light
ph
shift
compound
absorpt
devic
wash
procedur
use
remov
substanti
reduc
quantiti
residu
compound
transfus
provid
highest
possibl
safeti
margin
despit
reduct
level
residu
compound
trace
compound
remain
treat
product
rais
concern
potenti
longterm
toxic
recipi
process
personnel
environ
therefor
obtain
regulatori
approv
licensur
pathogen
inactiv
system
methodcompound
need
examin
independ
exampl
amotosalen
system
platelet
evalu
comprehens
toxicolog
program
includ
carcinogen
studi
anim
conform
requir
approv
pharmaceut
toxicolog
relev
find
tissu
organ
found
multipl
phase
iii
clinic
trial
well
postmarket
phase
iv
experi
intercept
platelet
provid
efficaci
safeti
data
pathogen
inactiv
process
limit
data
costeffect
pathogen
inactiv
system
econom
intervent
pathogen
inactiv
evalu
way
direct
net
cost
consequ
tradit
costeffect
analysi
net
cost
analysi
assess
direct
cost
blood
center
adopt
new
intervent
exampl
pathogen
inactiv
offer
potenti
avoid
cost
bacteri
test
cirradi
leukocyt
inactiv
cmv
serolog
test
thu
directli
impact
net
cost
new
technolog
tradit
costeffect
analysi
gener
use
qualityadjust
lifeyear
threshold
us
discrimin
costeffect
costineffect
intervent
howev
blood
safeti
intervent
nat
higher
qualityadjust
lifeyear
threshold
adopt
practic
standpoint
cost
logist
implement
pathogen
inactiv
system
need
consid
long
run
pathogen
inactiv
system
offer
potenti
insur
threat
emerg
pathogen
final
impact
pathogen
inactiv
reduc
donor
select
test
possibl
major
compon
deriv
blood
donat
subject
licens
pathogen
inactiv
techniqu
foundat
prevent
transfusiontransmit
infect
donor
screen
test
includ
serolog
test
nat
approach
led
signific
advanc
safeti
blood
suppli
respect
certain
pathogen
includ
hiv
hcv
hbv
howev
blood
suppli
continu
vulner
exampl
bacteri
contamin
platelet
remain
number
one
microbiolog
caus
transfusionrel
mortal
worldwid
respons
mani
death
year
blood
suppli
also
vulner
emerg
reemerg
pathogen
list
viral
parasit
bacteri
pathogen
could
potenti
threaten
blood
suppli
long
continu
grow
tabl
illustr
hiv
wnv
sar
new
pathogen
emerg
rapidli
spread
global
possibl
caus
seriou
morbid
mortal
recipi
infect
blood
product
although
test
success
reduc
risk
infect
highprofil
virus
remain
reactiv
strategi
continu
add
test
mani
known
yet
identifi
pathogen
continu
challeng
consid
cost
develop
implement
new
screen
assay
risk
test
error
furthermor
increasingli
stringent
donor
criteria
often
result
unnecessari
loss
mani
viabl
donor
addit
measur
includ
pathogen
inactiv
propos
altern
approach
reduc
risk
transfusiontransmit
infect
pathogen
inactiv
proactiv
altern
current
paradigm
develop
new
test
pathogen
threaten
safeti
blood
suppli
report
review
efficaci
sever
pathogen
inactiv
system
use
ffp
platelet
rbc
current
variou
stage
clinic
develop
preclin
studi
demonstr
pathogen
inactiv
technolog
target
broad
rang
nucleic
acidcontain
pathogen
maintain
vitro
function
treat
plasma
platelet
avail
system
proven
safe
efficaci
implement
worldwid
potenti
significantli
impact
safeti
blood
suppli
